CycloSal-phosphate pronucleotides of cytostatic 6-(Het)aryl-7-deazapurine ribonucleosides: Synthesis, cytostatic activity, and inhibition of adenosine kinases. 2010

Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Prague, Czech Republic.

A series of cycloSal-phosphate prodrugs of a recently described new class of nucleoside cytostatics (6-hetaryl-7-deazapurine ribonucleosides) was prepared. The corresponding 2',3'-isopropylidene 6-chloro-7-deazapurine nucleosides were converted into 5-O'-cycloSal-phosphates. These underwent a series of Stille or Suzuki cross-couplings with diverse (het)arylstannanes or -boronic acids to yield the protected 6-(het)aryl-7-deazapurine pronucleotides that were subsequently deprotected to give 12 derivatives of free pronucleotides. The in vitro cytostatic effect of the pronucleotides was compared with parent nucleoside analogues. In most cases, the activity of the pronucleotide was similar to or somewhat lower than that of the corresponding parent nucleosides, with the exception of 7-fluoro pronucleotides 13 a, 13 b, and 13 d, which had exhibited GIC(50) values that were improved by one order of magnitude (to the low nanomolar range). The presence of a cycloSal-phosphate group also influenced selectivity toward various cell lines. Several pronucleotides were found which strongly inhibit human adenosine kinase but only weakly inhibit the MTB adenosine kinase.

UI MeSH Term Description Entries
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011685 Purine Nucleotides Purines attached to a RIBOSE and a phosphate that can polymerize to form DNA and RNA. Nucleotides, Purine
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000248 Adenosine Kinase An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20. Kinase, Adenosine
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D054697 Cytostatic Agents Compounds that inhibit or prevent the proliferation of CELLS. Cytostatic,Cytostatic Agent,Cytostatic Drug,Cytostatic Drugs,Cytostatics,Agent, Cytostatic,Drug, Cytostatic

Related Publications

Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
June 2015, ChemMedChem,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
January 2011, Bioorganic & medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
February 2014, Journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
January 2010, Journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
December 2015, Bioorganic & medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
March 2017, Journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
July 2022, European journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
October 2014, Journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
August 2012, Journal of medicinal chemistry,
Pavla Spácilová, and Petr Naus, and Radek Pohl, and Ivan Votruba, and Jan Snásel, and Helena Zábranská, and Iva Pichová, and Ria Ameral, and Gabriel Birkus, and Tomás Cihlár, and Michal Hocek
October 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!